演題抄録

FACO Symposium

開催概要
開催回
第53回・2015年・京都
 

Advancement of Research and Clinical Practice on Hepatocellular Carcinoma in Asia

演題番号 : FS2-1

[筆頭演者]
Wang Chun-Hsiang:1 
[共同演者]
Mo Lein-Ray:1、Chang Kuo-Kwan:1、Lin Ruey-Chang:1、Kuo Jen-Juan:1、Wey Keh-Cherng:1

1:Department of Hepatogastroenterology, Tainan Municipal Hospital, Taiwan

 

AFP’s role in HCC diagnosis is relatively limited in patients with small HCC and HCC of normal AFP level. In this scenario, DCP, AFP-L3, and many other biomarkers have been accepted as better alternative tests. The issue of differentiating early HCC from dysplatic nodule (DN) used to be challenging by standardized radiological tools; however, it had recently been solved by Gd-EOB-DTPA-enhanced MRI in terms of hepatocyte-phase images. If there are still uncertainties about making definite diagnosis of HCC, histological features would be the last choice to solve the problems. Nevertheless, morphological characteristics alone sometimes are not evident enough to distinguish early HCC from DN. In this circumstances, thanks to the development of immunohistochemistry-cross-sectional diagnostic imaging markers of early HCC identified by genomic studies, GPC3 as well as several other protein markers may help clarify the inconsistencies and ambiguities.
During the past decades, management of HCC have been changing from single method to multidisciplinary treatment options as well as comprehensively taking into account variables of tumor stage, underlying liver function, performance status, comorbid conditions and life expectancy. The notions of individualized therapy of HCC suggest that the treatment strategy should be tailored on the single patient, which need to be highlighted in accordance to evidence-based treatment guidelines.
Compared with standard TACE procedure, embolization with doxorubicin DEB may confer a durable effects and favorable outcomes in unresectable, untransplantable, or unsuitable for local-regional treatment’s HCC patients. As a new therapy, radioembolization was developed and has now been implemented to improve outcomes and already had produced promising results. In addition to sorafenib being currently considered a standard treatment for HCC beyond early and intermediate stage, several second line of oral targeted anti-HCC agents have also been undergoing clinical trials.

前へ戻る